A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03952078 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
151
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Corvus Pharmaceuticals, Inc.